The Curcumin Derivative, H10, Suppresses Hormone-Dependent Prostate Cancer by Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3

Overview

Journal Front Pharmacol

Date 2020 May 28

PMID 32457626

Citations 3

Authors

Yating Cheng

Yan Yang

Yinan Wu

Wencheng Wang

Lichun Xiao

Yifan Zhang

Jianzhong Tang

Ya-Dong Huang

Shu Zhang

Qi Xiang

Affiliations

Soon will be listed here.

Abstract

The 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) enzyme is a potential therapeutic target for hormone-dependent prostate cancer, as it is the key enzyme in the last step of testosterone (T) biosynthesis. A curcumin analog, H10, was optimized for inhibiting T production in LC540 cells that stably overexpressed 17β-HSD3 enzyme (LC540 [17β-HSD3]) (P < 0.01), without affecting progesterone (P) synthesis. H10 downregulated the production of T in the microsomal fraction of rat testes containing the 17β-HSD3 enzyme from 100 to 78.41 ± 7.41%, 51.86 ± 10.03%, and 45.14 ± 8.49% at doses of 10, 20, and 40 μM, respectively. There were no significant differences among the groups with respect to the protein expression levels of 17β-HSD3, 3βHSD1, CYP17a1, CYP11a1, and STAR, which participate in 17β-HSD3-mediated conversion of androgens to T (P > 0.05). This indicated that H10 only inhibited the enzymatic activity of 17β-HSD3 . Furthermore, H10 inhibited the adione-stimulated growth of xenografts established from LNCaP cells in nude mice . We conclude that H10 could serve as an effective inhibitor of 17β-HSD3, which in turn would inhibit the biosynthesis of androgens and progression of prostate cancer.

Citing Articles

Application and potential value of curcumin in prostate cancer: a meta-analysis based on animal models.

Wang S, Zhang F, Chen J Front Pharmacol. 2024; 15:1379389.

PMID: 38783940 PMC: 11111872. DOI: 10.3389/fphar.2024.1379389.

Attenuation of Scopolamine-Induced Amnesia via Cholinergic Modulation in Mice by Synthetic Curcumin Analogs.

Hussain H, Ahmad S, Ali Shah S, Ullah A, Ali N, Almehmadi M Molecules. 2022; 27(8).

PMID: 35458662 PMC: 9029618. DOI: 10.3390/molecules27082468.

Potential Role of Curcumin for the Treatment of Major Depressive Disorder.

Lopresti A CNS Drugs. 2022; 36(2):123-141.

PMID: 35129813 PMC: 8863697. DOI: 10.1007/s40263-022-00901-9.

References

Djigoue G, Kenmogne L, Roy J, Maltais R, Poirier D . Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg Med Chem. 2015; 23(17):5433-51. DOI: 10.1016/j.bmc.2015.07.049. View

Estevez S, Herranz U, Fernandez Calvo O, Afonso Afonso F, Santome Couto L, Lazaro Quintela M . Prostate cancer perspectives after chaarted: Optimizing treatment sequence. Crit Rev Oncol Hematol. 2016; 107:119-127. DOI: 10.1016/j.critrevonc.2016.08.007. View

Nuti E, Bassani B, Camodeca C, Rosalia L, Cantelmo A, Gallo C . Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues. Eur J Med Chem. 2017; 138:890-899. DOI: 10.1016/j.ejmech.2017.07.024. View

Yazawa T, Imamichi Y, Uwada J, Sekiguchi T, Mikami D, Kitano T . Evaluation of 17β-hydroxysteroid dehydrogenase activity using androgen receptor-mediated transactivation. J Steroid Biochem Mol Biol. 2019; 196:105493. DOI: 10.1016/j.jsbmb.2019.105493. View

Kunnumakkara A, Bordoloi D, Harsha C, Banik K, Gupta S, Aggarwal B . Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci (Lond). 2017; 131(15):1781-1799. DOI: 10.1042/CS20160935. View

Rice M, V Malhotra S, Stoyanova T . Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019; 9:801. PMC: 6723105. DOI: 10.3389/fonc.2019.00801. View

Bacsa I, Jojart R, Wolfling J, Schneider G, Herman B, Szecsi M . Synthesis of novel 13α-estrone derivatives by Sonogashira coupling as potential 17β-HSD1 inhibitors. Beilstein J Org Chem. 2017; 13:1303-1309. PMC: 5496578. DOI: 10.3762/bjoc.13.126. View

Morote J, Maldonado X, Morales-Barrera R . [Prostate cancer]. Med Clin (Barc). 2015; 146(3):121-7. DOI: 10.1016/j.medcli.2014.12.021. View

Kenmogne L, Maltais R, Poirier D . Synthesis of a dansyl-labeled inhibitor of 17β-hydroxysteroid dehydrogenase type 3 for optical imaging. Bioorg Med Chem Lett. 2016; 26(9):2179-83. DOI: 10.1016/j.bmcl.2016.03.069. View

10.

Yuan X, Li H, Bai H, Su Z, Xiang Q, Wang C . Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties. Eur J Med Chem. 2014; 77:223-30. DOI: 10.1016/j.ejmech.2014.03.012. View

11.

Barbosa J, de Figueiredo S, Monteiro F, Rocha-Silva F, Gaciele-Melo C, Coelho S . New Approaches on Leishmaniasis Treatment and Prevention: A Review of Recent Patents. Recent Pat Endocr Metab Immune Drug Discov. 2015; 9(2):90-102. DOI: 10.2174/1872214809666150921111956. View

12.

Yang J, Ning J, Peng L, He D . Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer. Int J Clin Exp Pathol. 2015; 8(8):9272-8. PMC: 4583908. View

13.

Sim J, Cho B, Park M, Rhee J, In S, Choe S . Monitoring urinary testosterone and epitestosterone levels, and their ratio, in Korean chemical castration subjects using liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2019; 44(2):192-199. DOI: 10.1093/jat/bkz002. View

14.

Yu Y, Liu C, Wang B, Li Y, Zhang H . Characterization of 3,17β-hydroxysteroid dehydrogenase in Comamonas testosteroni. Chem Biol Interact. 2015; 234:221-8. DOI: 10.1016/j.cbi.2015.01.005. View

15.

Cortes-Benitez F, Roy J, Perreault M, Maltais R, Poirier D . A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships. J Med Chem. 2019; 62(15):7070-7088. DOI: 10.1021/acs.jmedchem.9b00624. View

16.

Kenmogne L, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F . Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models. PLoS One. 2017; 12(2):e0171871. PMC: 5300232. DOI: 10.1371/journal.pone.0171871. View

17.

Teoh J, Hirai H, Ho J, Chan F, Tsoi K, Ng C . Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One. 2019; 14(10):e0221775. PMC: 6812812. DOI: 10.1371/journal.pone.0221775. View

18.

Pourbasheer E, Vahdani S, Malekzadeh D, Aalizadeh R, Ebadi A . QSAR Study of 17β-HSD3 Inhibitors by Genetic Algorithm-Support Vector Machine as a Target Receptor for the Treatment of Prostate Cancer. Iran J Pharm Res. 2017; 16(3):966-980. PMC: 5610752. View

19.

Pascal L, Masoodi K, OMalley K, Shevrin D, Gingrich J, Parikh R . 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol. 2014; 193(4):1388-93. PMC: 4404193. DOI: 10.1016/j.juro.2014.10.101. View

20.

Ganjali S, Blesso C, Banach M, Pirro M, Majeed M, Sahebkar A . Effects of curcumin on HDL functionality. Pharmacol Res. 2017; 119:208-218. DOI: 10.1016/j.phrs.2017.02.008. View